clinical trial · NCT06248606
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Ryan Gentzler, MD·phase2·recruiting·n = 30
Non Small Cell Lung CancerNSCLCKRAS G12CAdagrasibStereotactic Radiosurgery
brief summary
This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.
started
Aug 6, 2024
primary completion
Feb 25, 2027
completion
Feb 25, 2028
last updated
Apr 8, 2026
official title
Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol